As long as logic is still legal (it still is in some states, so I will apply the force and protection of the interstate commerce clause in saying these things), I will apply logic to the usual confusion
Bret initially fashioned the covid modification in NNLX's Ohio lab.
the 8-7-20 update was to refine that work and as per the language used in the 8-7 update the refinement was already underway, as evidenced by "further developments" "begins" "has begun working" plus "mutual confidentiality agreements" the latter of which often can involve a lot of work and back and forth between NNLX and the CA diagnostics company.
If that CA company is the same CA company NNLX last was involved with-which is likely-as the 6-3 PR apparently didnt drum up additional interest, that would allow the business side agreement w NNLX to be made quickly and would also pave the way for the CA work to be in progress by the time of the 8-7 update. Although the covid test is not the same as the n-assay but some form of modification the Faros would still be involved as the n-assay was at least part if not mostly their baby.
Assuming the 8-7 update Houston lab is The Faros- very likely- the Faros would not need to rely on a grant to proceed. Instead, as usual, they are working with NNLX for their financing.
Thus the grant sought by "at least one party" is almost absolutely assuredly the CA diagnostics co, which previously sought a grant for their former alignment w NNLX.
Business metrics /philosophy are obsessive today- beyond any natural explanation- and thus in the obsessive search for the bottom line, grants as a funding method exploded geometrically in the last 40 years. Grants upfront were not necessary for the CA work and could be applied mid-stream or even post-stream, though it is possible for he CA co to pull out at any time if the contract so allows.
But dont assume the CA co backed out. This last update would've been the perfect vehicle for NNLX to inform us if the CA co had pulled out. And in the interests of honesty, if NNLX were SEC reporting I believe they would be required to so notify us. Since NNLX is not SEC reporting we cannot be so assured but the standards are influential, if not persuasive.
So there are 2 possibilities re the CA company-the usual parties are assuming it pulled out and the new co is taking over.
the other possibility is the CA co is still involved- the 8-7 update stated. purpose "to refine and further develop its patent-pending Rapid Viral Assay for COVID19 and other viruses."
This sounds like it could be a different purpose than testing the newly refined product on an actual commercial platform. Those who are actually in the bio tech field might be able to comment further.
The 8-7 CA company refining the product and the latest announcement company testing the refinement on its commercial platform.
That would be the logical progression - the major transition from product creation to product commercialization that is the seize the day moment of every company.
"NanoLogix has enlisted the services of a company with an advanced diagnostic platform that can deliver lab-quality results at point-of-care (POC). That company will perform an initial feasibility assessment of our COVID-19 viral assay on their rapid POC system."
Read More: https://investorshangout.com/post/newpost/648...z6a3Aq6sGQ
So the new co can be more advanced diagnostics plus coupled with the commercialization platform.
What might inveigh against that logical progression is if a separate EUA was required-though that could be for the commercial refinement- i thought i saw something re a separate eua to be sought when i first read the post but dont see any mention of such in the update below posted by nanobuyer.
Given the advantages of NNLX superior product, as succinctly reported by Mach, Mits and others, and the all encompassing nature of the pandemic, the CA company would have to be idiots to pull out- there are plenty of idiots running this world but they usually dont commit financial suicide as the CA co seemingly would be doing by pulling out.
If u are a diagnostics co and have the opportunity to participate in an innovation re the pandemic of the century after already completing the business side agreements w NNLX, why wouldnt you finish the diagnostics? Unless the CA co is a shoestring operation but if its the same CA co NNLX previously partnered with it shouldnt be a shoe string operation. Things NNLX has said in the past indicate otherwise.
Update
NanoLogix Sub 1-Hour Covid-19 Detection Test Further Developments
NanoLogix Begins Collaborative Efforts With Diagnostic Company and an Independent Laboratory
NanoLogix announces it has begun working with two entities to refine and further develop its patent-pending Rapid Viral Assay for COVID19 and other viruses. One is a West Coast diagnostic company and the other a long-established independent Houston laboratory.
The overall intent of this work is to obtain results to enable a detailed submission of those results to the US FDA for the purpose of receiving an Emergency Use Authorization, enabling use of the technology as a Point of Care (POC) rapid test. Secondary benefits should be publication of the resulting data in the form of at least two peer-reviewed science/medical journal papers. Grant applications are anticipated by at least one of the partners to the work. The projections for the timeline for the work range from one+ month for the independent laboratory to more than three months for the diagnostic company.
Friday, August 7, 2020 10:29:11 AM
Post#
6969
of 6989
(Total Views: 134)
Posted On: 08/07/2020 8:22:19 AM
Posted By: Eudius
Update
NanoLogix Sub 1-Hour Covid-19 Detection Test Further Developments
NanoLogix Begins Collaborative Efforts With Diagnostic Company and an Independent Laboratory
NanoLogix announces it has begun working with two entities to refine and further develop its patent-pending Rapid Viral Assay for COVID19 and other viruses. One is a West Coast diagnostic company and the other a long-established independent Houston laboratory.
The overall intent of this work is to obtain results to enable a detailed submission of those results to the US FDA for the purpose of receiving an Emergency Use Authorization, enabling use of the technology as a Point of Care (POC) rapid test. Secondary benefits should be publication of the resulting data in the form of at least two peer-reviewed science/medical journal papers. Grant applications are anticipated by at least one of the partners to the work. The projections for the timeline for the work range from one+ month for the independent laboratory to more than three months for the diagnostic company.
While we have achieved results in less than one hour with our own laboratory work, indications from one of the entities are that the test can potentially be streamlined to the point where results may be obtained in as little as twenty minutes in a form that makes the test more user and consumer friendly. This projected ease of use positions the assay for potential home use if and when it is approved by the FDA.
NanoLogix has entered into mutual confidentiality agreements with both involved groups. We faithfully respect those agreements as essential to the success of business and technology development. In the past, when we have released information mentioning arrangements with others, such as the US EPA, the University of Texas Health Science Center in Houston, Battelle Biomedical research Center, and individuals recently employed or otherwise associated with NanoLogix, those groups began receiving calls and contacts from persons identifying themselves as shareholders of NanoLogix. The calls ranged from in subject from simple curiousity to demands to reveal the nature of the technology development and business relationship with NanoLogix. The effects were potentially damaging to NanoLogix and its interests, to include investors. We will not release further information regarding the recent associations until all parties are prepared to do so.
This press release or update contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Read More: https://investorshangout.com/post/view?id=585...z6URlniueu
Read More: https://investorshangout.com/Nanologix-Inc-NN...z6a30c4z3V
Bret initially fashioned the covid modification in NNLX's Ohio lab.
the 8-7-20 update was to refine that work and as per the language used in the 8-7 update the refinement was already underway, as evidenced by "further developments" "begins" "has begun working" plus "mutual confidentiality agreements" the latter of which often can involve a lot of work and back and forth between NNLX and the CA diagnostics company.
If that CA company is the same CA company NNLX last was involved with-which is likely-as the 6-3 PR apparently didnt drum up additional interest, that would allow the business side agreement w NNLX to be made quickly and would also pave the way for the CA work to be in progress by the time of the 8-7 update. Although the covid test is not the same as the n-assay but some form of modification the Faros would still be involved as the n-assay was at least part if not mostly their baby.
Assuming the 8-7 update Houston lab is The Faros- very likely- the Faros would not need to rely on a grant to proceed. Instead, as usual, they are working with NNLX for their financing.
Thus the grant sought by "at least one party" is almost absolutely assuredly the CA diagnostics co, which previously sought a grant for their former alignment w NNLX.
Business metrics /philosophy are obsessive today- beyond any natural explanation- and thus in the obsessive search for the bottom line, grants as a funding method exploded geometrically in the last 40 years. Grants upfront were not necessary for the CA work and could be applied mid-stream or even post-stream, though it is possible for he CA co to pull out at any time if the contract so allows.
But dont assume the CA co backed out. This last update would've been the perfect vehicle for NNLX to inform us if the CA co had pulled out. And in the interests of honesty, if NNLX were SEC reporting I believe they would be required to so notify us. Since NNLX is not SEC reporting we cannot be so assured but the standards are influential, if not persuasive.
So there are 2 possibilities re the CA company-the usual parties are assuming it pulled out and the new co is taking over.
the other possibility is the CA co is still involved- the 8-7 update stated. purpose "to refine and further develop its patent-pending Rapid Viral Assay for COVID19 and other viruses."
This sounds like it could be a different purpose than testing the newly refined product on an actual commercial platform. Those who are actually in the bio tech field might be able to comment further.
The 8-7 CA company refining the product and the latest announcement company testing the refinement on its commercial platform.
That would be the logical progression - the major transition from product creation to product commercialization that is the seize the day moment of every company.
"NanoLogix has enlisted the services of a company with an advanced diagnostic platform that can deliver lab-quality results at point-of-care (POC). That company will perform an initial feasibility assessment of our COVID-19 viral assay on their rapid POC system."
Read More: https://investorshangout.com/post/newpost/648...z6a3Aq6sGQ
So the new co can be more advanced diagnostics plus coupled with the commercialization platform.
What might inveigh against that logical progression is if a separate EUA was required-though that could be for the commercial refinement- i thought i saw something re a separate eua to be sought when i first read the post but dont see any mention of such in the update below posted by nanobuyer.
Given the advantages of NNLX superior product, as succinctly reported by Mach, Mits and others, and the all encompassing nature of the pandemic, the CA company would have to be idiots to pull out- there are plenty of idiots running this world but they usually dont commit financial suicide as the CA co seemingly would be doing by pulling out.
If u are a diagnostics co and have the opportunity to participate in an innovation re the pandemic of the century after already completing the business side agreements w NNLX, why wouldnt you finish the diagnostics? Unless the CA co is a shoestring operation but if its the same CA co NNLX previously partnered with it shouldnt be a shoe string operation. Things NNLX has said in the past indicate otherwise.
Update
NanoLogix Sub 1-Hour Covid-19 Detection Test Further Developments
NanoLogix Begins Collaborative Efforts With Diagnostic Company and an Independent Laboratory
NanoLogix announces it has begun working with two entities to refine and further develop its patent-pending Rapid Viral Assay for COVID19 and other viruses. One is a West Coast diagnostic company and the other a long-established independent Houston laboratory.
The overall intent of this work is to obtain results to enable a detailed submission of those results to the US FDA for the purpose of receiving an Emergency Use Authorization, enabling use of the technology as a Point of Care (POC) rapid test. Secondary benefits should be publication of the resulting data in the form of at least two peer-reviewed science/medical journal papers. Grant applications are anticipated by at least one of the partners to the work. The projections for the timeline for the work range from one+ month for the independent laboratory to more than three months for the diagnostic company.
Friday, August 7, 2020 10:29:11 AM
Post#
6969
of 6989
(Total Views: 134)
Posted On: 08/07/2020 8:22:19 AM
Posted By: Eudius
Update
NanoLogix Sub 1-Hour Covid-19 Detection Test Further Developments
NanoLogix Begins Collaborative Efforts With Diagnostic Company and an Independent Laboratory
NanoLogix announces it has begun working with two entities to refine and further develop its patent-pending Rapid Viral Assay for COVID19 and other viruses. One is a West Coast diagnostic company and the other a long-established independent Houston laboratory.
The overall intent of this work is to obtain results to enable a detailed submission of those results to the US FDA for the purpose of receiving an Emergency Use Authorization, enabling use of the technology as a Point of Care (POC) rapid test. Secondary benefits should be publication of the resulting data in the form of at least two peer-reviewed science/medical journal papers. Grant applications are anticipated by at least one of the partners to the work. The projections for the timeline for the work range from one+ month for the independent laboratory to more than three months for the diagnostic company.
While we have achieved results in less than one hour with our own laboratory work, indications from one of the entities are that the test can potentially be streamlined to the point where results may be obtained in as little as twenty minutes in a form that makes the test more user and consumer friendly. This projected ease of use positions the assay for potential home use if and when it is approved by the FDA.
NanoLogix has entered into mutual confidentiality agreements with both involved groups. We faithfully respect those agreements as essential to the success of business and technology development. In the past, when we have released information mentioning arrangements with others, such as the US EPA, the University of Texas Health Science Center in Houston, Battelle Biomedical research Center, and individuals recently employed or otherwise associated with NanoLogix, those groups began receiving calls and contacts from persons identifying themselves as shareholders of NanoLogix. The calls ranged from in subject from simple curiousity to demands to reveal the nature of the technology development and business relationship with NanoLogix. The effects were potentially damaging to NanoLogix and its interests, to include investors. We will not release further information regarding the recent associations until all parties are prepared to do so.
This press release or update contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Read More: https://investorshangout.com/post/view?id=585...z6URlniueu
Read More: https://investorshangout.com/Nanologix-Inc-NN...z6a30c4z3V
4
